Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
Headlines
Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang
2026.10.02
Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou
2026.10.02
Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits
2026.09.30
2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma
2026.09.30
Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology
2026.09.29
Professor Bingcheng Liu: Exploring B-ALL from Personalized Immunity to Precision Immunotherapy | 2026 China-France Scientific Symposium on Hematology and Immunology
2026.09.29
CSCO 2026 Global Perspective | Professor Franco Cavalli: From Teaching to Learning—Witnessing China’s Transformation in Oncology and Exploring Lymphoma Frontiers and ICML 2027 Highlights
2026.09.29
Professor Benkang Shi: Advancing Standardization and Precision—Challenges, Pathways, and Future Directions in Prostate Cancer Care in China | Pujiang Prostate Cancer Academic Conference
2026.09.29
2026 Pujiang Urologic Oncology Academic Conference | Professor Xiaojie Bian: ADCs Across the Entire Urothelial Carcinoma Treatment Continuum—Balancing Sequencing and Safety, From Earlier-Line Treatment to Cross-Payload Sequencing Strategies
2026.09.29
CACA GU | Professor Zhenghua Ju: Overcoming the Challenges of Precise Laparoscopic Suturing—From the Challenges of Vesicourethral Anastomosis and the 360° Suturing Theory to the Three Fundamental Principles of Surgical Suturing
2026.09.28
Posted inUncategorized

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang

Posted by By Peng Longmei 2026.10.02
Continue Reading
Posted inUroStream

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Posted by By Mourabit Halima 2026.10.02
Continue Reading

Prof. Evangelos Terpos on Key Biomarkers in the EHA–EMN Guidelines for Multiple Myeloma

Posted by By Mourabit Halima 2025.07.02
Read More
Deciphering Precision Immunotherapy for Gastric Cancer: Insights from Evolving Guidelines

Deciphering Precision Immunotherapy for Gastric Cancer: Insights from Evolving Guidelines

Posted by By Peng Longmei 2025.07.02
Read More
Immunotherapy for Locally Advanced Gastric Cancer: Current Landscape and Future Directions​

Immunotherapy for Locally Advanced Gastric Cancer: Current Landscape and Future Directions​

Posted by By Peng Geng 2025.07.02
Read More
Human Proteome Navigation Initiative

Human Proteome Navigation Initiative

Posted by By Peter W. PENG 2025.07.01
Read More
Organoids in Gastric Cell Differentiation and Drug Sensitivity Testing for Gastric Cancer

Organoids in Gastric Cell Differentiation and Drug Sensitivity Testing for Gastric Cancer

Posted by By Mourabit Halima 2025.07.01
Read More
Precision Therapeutics in Upper GI Cancers: Advances and Applications​

Precision Therapeutics in Upper GI Cancers: Advances and Applications​

Posted by By Lisa Cui 2025.07.01
Read More
ASCO | Professor Dickon Hayne Shares ANZUP 1301 Findings: Combined Mitomycin Intravesical Therapy May Help Alleviate BCG Shortage in High-Risk NMIBC

ASCO | Professor Dickon Hayne Shares ANZUP 1301 Findings: Combined Mitomycin Intravesical Therapy May Help Alleviate BCG Shortage in High-Risk NMIBC

Posted by By Mourabit Halima 2025.07.01
Editor’s note: Bacillus Calmette–Guérin (BCG) is the standard intravesical therapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC). However, in some countries and regions, BCG shortages remain a challenge, limiting…
Read More
Power of softness in mechano-onco-immunology

Power of softness in mechano-onco-immunology

Posted by By Mourabit Halima 2025.07.01
Read More
Tumor: A Special Metabolic Disease

Tumor: A Special Metabolic Disease

Posted by By Peng Longmei 2025.07.01
Read More
Experience in Precision Treatment of Esophageal Cancer

Experience in Precision Treatment of Esophageal Cancer

Posted by By Mourabit Halima 2025.07.01
Read More

Posts pagination

Previous page 1 … 20
Recent Posts
  • Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang
  • Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou
  • Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits
  • 2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma
  • Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    Post You Might Like
    Posted inUncategorized
    Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang
    Posted by By Peng Longmei 2026.10.02
    Posted inUroStream
    Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou
    Posted by By Mourabit Halima 2026.10.02
    Posted inUroStream
    Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits
    Posted by By Peter W. PENG 2026.09.30
    Posted inUroStream
    2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma
    Posted by By Mourabit Halima 2026.09.30
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top

    Welcome to Mediamedic 👋
    It’s nice to meet you.

    Dive into a world of trusted health insights. Subscribe for monthly updates straight to your inbox

    Privacy is part of our care. No spam, just wellness.

    🔒 Privacy policy

    Check your inbox or spam folder to confirm your subscription.

    • Facebook
    • X (Twitter)
    • LinkedIn
    • More Networks
    Share via
    Facebook
    X (Twitter)
    LinkedIn
    Mix
    Email
    Print
    Copy Link
    Copy link
    CopyCopied